Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sells $67,538.75 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Stock Performance

NASDAQ:HRMY opened at $39.54 on Friday. The firm has a market cap of $2.26 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The business has a 50 day moving average price of $35.20 and a 200-day moving average price of $35.22.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Trading of Harmony Biosciences

A number of institutional investors have recently made changes to their positions in HRMY. Pacer Advisors Inc. lifted its stake in Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. Dimensional Fund Advisors LP lifted its stake in Harmony Biosciences by 13.3% in the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after acquiring an additional 112,197 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after acquiring an additional 140,690 shares during the period. Millennium Management LLC lifted its stake in Harmony Biosciences by 51.6% in the second quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock worth $9,275,000 after acquiring an additional 104,691 shares during the period. Finally, Marshall Wace LLP lifted its stake in Harmony Biosciences by 145.4% in the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after acquiring an additional 181,092 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

HRMY has been the subject of a number of recent analyst reports. Cantor Fitzgerald lifted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Mizuho boosted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James restated an “outperform” rating and issued a $40.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Harmony Biosciences in a research report on Monday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.